Table 4 Feasibility of orphan drug incentives for neglected diseases
From: Expert Delphi survey on research and development into drugs for neglected diseases
| Â | Â | % (n) | % (n) | % (n) | % (n) | % (n) | Â | Â |
|---|---|---|---|---|---|---|---|---|
| Â | Â | very (definitely) feasible | feasible | unfeasible | definitely unfeasible | no judgment | Total valid % (n) | Total N (Missing) |
Market exclusivity | Round I | 10% (11) | 28,2% (31) | 20,9% (23) | 2,7% (3) | 38,2% (42) | 110 | 159 (49) |
| Â | Round II | 13.7% (7) | 27.5% (14) | 27.5% (14) | 2.0% (1) | 29.4% (15) | 51 | 77 (26) |
Tax credits | Round I | 21.8% (24) | 40,0% (44) | 4,5% (5) | 2,7% (3) | 30,9% (34) | 110 | 159 (49) |
| Â | Round II | 35.3% (18) | 37.3% (19) | 5.9% (3) | 2.0 (1) | 19.6% (10) | 51 | 77 (26) |
Protocol assistance | Round I | 32.7% (36) | 44,5% (49) | 1.8% (2) | 0,0% (0) | 20.9% (23) | 110 | 159 (50) |
| Â | Round II | 35,3% (18) | 52.9% (27) | 3.9% (2) | 0.0% (0) | 7.8% (4) | 51 | 77 (26) |
Fee reduction/Fee waivers (e.g. for marketing approval, scientific advice) | Round I | 26,6% (29) | 51.4% (56) | 4.6% (5) | 0,9% (1) | 16.5% (18) | 110 | 159 (49) |
| Â | Round II | 23.1% (12) | 50.0% (26) | 11.5% (6) | 0.0% (0) | 15.4% (8) | 52 | 77 (25) |